CODX vs. NMTC, COCH, TMDIF, DRIO, OSRH, BDMD, FEMY, VVOS, PETV, and RVP
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include NeuroOne Medical Technologies (NMTC), Envoy Medical (COCH), Titan Medical (TMDIF), DarioHealth (DRIO), OSR (OSRH), Baird Medical Investment (BDMD), Femasys (FEMY), Vivos Therapeutics (VVOS), PetVivo (PETV), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs. Its Competitors
Co-Diagnostics (NASDAQ:CODX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Co-Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Co-Diagnostics' average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score.
Co-Diagnostics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Co-Diagnostics currently has a consensus price target of $5.50, indicating a potential upside of 2,007.28%. NeuroOne Medical Technologies has a consensus price target of $1.45, indicating a potential upside of 98.36%. Given Co-Diagnostics' higher probable upside, equities analysts plainly believe Co-Diagnostics is more favorable than NeuroOne Medical Technologies.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 6.1% of Co-Diagnostics shares are held by company insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NeuroOne Medical Technologies has a net margin of -75.41% compared to Co-Diagnostics' net margin of -1,025.45%. Co-Diagnostics' return on equity of -60.16% beat NeuroOne Medical Technologies' return on equity.
Summary
NeuroOne Medical Technologies beats Co-Diagnostics on 7 of the 13 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 7/8/2025 by MarketBeat.com Staff
Free CODX Stock Alerts